Usana Health Sciences Inc income statement

In fiscal 2025, Usana Health Sciences Inc reported revenue of $925m, up 8.3% on the year before, operating income of $37.4m (a 4.0% margin) and net income of $10.8m, or $0.58 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Usana Health Sciences Inc: income statement, annual
Fiscal year	2009Jan 2010	2010Jan 2011	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Jan 2015	2015Jan 2016	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Jan 2021	2021Jan 2022	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Jan 2026	LTMJul 2026
Revenue	437	518	582	649	718	790	918	1,006	1,047	1,189	1,061	1,135	1,186	999	921	855	925	913
Cost of revenue	—	—	—	—	—	—	—	180	179	201	188	209	218	194	177	161	201	206
Gross profit	347	422	480	533	591	650	759	826	868	989	873	926	969	805	744	693	724	707
Research and development	—	4	4	5	5	5	6	9	9	10	10	11	11	12	11	12	11	—
Selling, general and administrative	100	121	137	154	166	185	209	234	265	275	268	261	279	262	257	263	337	335
Operating income	51	68	77	98	117	116	142	139	133	188	146	176	170	108	93	66	37	−1
Interest expense	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0
Income before tax	51	69	77	98	117	116	143	139	135	192	150	178	171	109	102	76	42	3
Income tax	17	23	27	32	38	39	48	39	72	65	50	53	54	39	39	34	30	32
Net income	34	46	51	66	79	77	95	100	63	126	101	125	117	69	64	42	11	−22
Diluted EPS	$1.08	$1.43	$1.63	$2.23	$2.78	$2.80	$3.59	$3.99	$2.53	$5.12	$4.41	$5.86	$5.73	$3.59	$3.30	$2.19	$0.58	−$1.21
Diluted shares (average)	31m	32m	31m	30m	28m	27m	26m	25m	25m	25m	23m	21m	20m	19m	19m	19m	19m	18m
EBITDA	58	76	86	107	126	125	152	152	149	205	161	190	183	121	106	81	70	31

US$ millions unless shown otherwise. Fiscal quarters.

Usana Health Sciences Inc: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Jan 2026	2026 Q1Apr 2026	2026 Q2Jul 2026
Revenue	200	214	250	236	214	226	250	223
Cost of revenue	39	39	52	50	49	49	59	48
Gross profit	161	175	197	186	165	177	191	175
Selling, general and administrative	61	73	91	82	86	78	88	82
Operating income	16	8	16	17	1	4	14	−20
Interest expense	0	0	0	0	0	0	0	0
Income before tax	19	10	17	19	2	4	15	−19
Income tax	8	6	7	8	8	6	9	9
Net income	11	4	9	10	−7	−2	8	−21
Diluted EPS	$0.56	$0.23	$0.49	$0.52	−$0.36	−$0.09	$0.41	−$1.16
EBITDA	19	12	24	24	9	12	22	−12

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ODD vs USNA NUS vs USNA IPAR vs USNA NATR vs USNA

More: Personal Care Products stocks compared, Consumer Staples sector, rankings of US companies

Figures from Usana Health Sciences Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Usana Health Sciences Inc.